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Ovarian cancer is a morphologically and biologically heterogeneous disease. The identification of
type-specific protein markers for ovarian cancer would provide the basis for more tailored treat-
ments, as well as clues for understanding the molecular mechanisms governing cancer pro-
gression. In the present study, we used a novel approach to classify 24 ovarian cancer tissue
samples based on the proteomic pattern of each sample. The method involved fractionation
according to pI using chromatofocusing with analytical columns in the first dimension followed
by separation of the proteins in each pI fraction using nonporous RP HPLC, which was coupled
to an ESI-TOF mass analyzer for molecular weight (MW) analysis. A 2-D mass map of the pro-
tein content of each type of ovarian cancer tissue samples based upon pI versus intact protein
MW was generated. Using this method, the clear cell and serous ovarian carcinoma samples
were histologically distinguished by principal component analysis and clustering analysis based
on their protein expression profiles and subtype-specific biomarker candidates of ovarian cancers
were identified, which could be further investigated for future clinical study.
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1 Introduction
Ovarian carcinoma is the fifth most common cancer in
American woman and the fifth most common cause of can-
cer-related deaths [1]. Over 70% of women with ovarian can-
cer are diagnosed when the disease is advanced beyond the
pelvis [2]. The 5-year survival rate for patients diagnosed with
ovarian cancer has remained under 30% for many years de-
spite the development of new treatments. Malignant ovarian
epithelial neoplasms (carcinomas) are both morphologically
and biologically heterogeneous. Based on morphological cri-
teria, there are four major histological types of primary ovar-
ian carcinomas (serous, clear cell, endometrioid, and muci-
nous). The serous carcinomas comprise about one-half of all
ovarian carcinomas and account for the majority of ovarian
cancer-related deaths. Although clear cell carcinomas are
much less common, several studies have noted their partic-
ularly unfavorable prognosis, even when corrected for tumor
stage [3–5]. In addition to molecular studies suggesting that
the different histological types of ovarian cancers likely
represent distinct disease entities [6–9], studies based on
comprehensive gene expression profiling have shown that
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clear cell carcinomas can be distinguished from other poor
prognosis ovarian carcinomas (e.g. serous carcinomas) based
on their distinctive gene expression signature [8]. Under-
standing the gene expression patterns characterizing each
morphological type of ovarian cancer may eventually lead to
the development of new type-specific diagnostic and/or
therapeutic strategies that might significantly improve sur-
vival, particularly amongst women with serous and clear cell
ovarian carcinomas.
Although cancer can be described as a disease of genes,
the protein products of genes are actually the functional
effector molecules that manifest the genetic information.
Characterization of protein expression for each morphologi-
cal type of ovarian cancer could lead to biologic insights and
potential improvements in specific and effective diagnosis
and treatments for this disease. LC-MS based multi-dimen-
sional separation methods are rapidly emerging for large-
scale protein expression profiling analysis to identify the
relative quantities of the various proteins between samples
[10–14]. We herein report a 2-D liquid phase mass mapping
method to explore protein-based expression profiling for
ovarian cancer classification and to search for subtype-spe-
cific biomarker candidates. In previous work, we have
demonstrated that high-resolution 2-D mass maps of human
cancer cell lines can be generated by this method with excel-
lent reproducibility, allowing accurate interlysate compar-
ison among different samples over the desired pI range [15,
16]. In addition, proteins in the range from 5 to 85 kDa can
be identified by MALDI-TOF MS based on PMF and con-
firmed by LC-MS/MS with high confidence combined with
pI and protein intact Mr information. In the present work, 2-
D mass mapping was applied to profile the proteome of pri-
mary clear cell and serous ovarian carcinoma tissue samples.
Proteins extracted from each tissue sample were fractioned
by chromatofocusing (CF) based on pI in the first dimen-
sion, further separated by RP-HPLC in the second dimen-
sion and subsequently analyzed by online ESI-TOF to obtain
intact protein Mr. Two protein-rich pI fractions (pH 5.4–5.2
and pH 5.2–5.0) were selected for interlysate comparisons of
protein content between the two different histological types
of ovarian tumor tissue samples (see Supplementary Figs. 1
and 3). Statistical analysis of the protein expression pattern
was able to correctly differentiate clear cell from serous sub-
types of ovarian cancers. In addition, significant differen-
tially expressed proteins as type-specific marker candidates
were identified, which could lead to development of new
strategies for the diagnosis and treatment of these cancers.
2 Materials and methods
2.1 Tumor tissues lysis
The proteomes of 24 ovarian cancer tissue samples (16 clear
cell carcinomas and 8 serous carcinomas) were profiled in
this study with approval from the University of Michigan’s
Institutional Review Board (IRBMED 1999-0428). Thirteen
carcinoma specimens were obtained from the Cooperative
Human Tissue Network/Gynecologic Oncology Group Tis-
sue Bank, seven from the University of Michigan Health
System, and four from Kumamoto University Hospital.
Available clinico-pathological data associated with tumor
specimens are provided in Table 1. All tumors were promptly
snap frozen after resection and stored at 2807C until the
time of analysis. Hematoxylin- and eosin-stained frozen sec-
tions of tumor immediately adjacent to the tissue lysed for
proteomic analysis were examined to ensure the presence of
at least 70% tumor cells. Tumor tissues were minced with
razor blades and subsequently sealed into 2-mL screw-cap
microcentrifuge vials (BioSpec Products, OK), containing
hundreds of minute glass beads (BioSpec Products). Vials
were subsequently filled with lysis buffer (7.5 M urea,
2.5 M thiourea, 12.5% glycerol, 50 mM Tris, 2.5% n-OG,
6.25 mM TCEP, 1.25 mM protease inhibitor, pH adjusted to
7.4) with no air bubbles. Tissue samples were homogenized
for 3 min in 10-s increments at 4800 rpm in a mini-bead
beater cell disruptor followed by centrifuging at 5000 rpm for
10 min at room temperature to pellet the bead mix. The
supernatant containing proteins were collected and stored
on ice. To avoid incomplete tissue disruption and protein
Table 1. Summary of ovarian carcinoma samples






KU-OC-002 48 3a) 2B
KU-OC-003 43 3a) 1A
KU-OC-006 55 3a) 1A
KU-OC-007 65 3a) 1C
CHTN-OC-003 74 3a) 3
CHTN-OC-004 48 3a) 3C
CHTN-OC-006 67 3a) 1
CHTN-OC-012 51 3a) 4
CHTN-OC-025 58 3a) 3
CHTN-OC-032 54 3a) 1
CHTN-OC-034 62 3a) 1
CHTN-OC-043 55 3a) 1
UM-OC-1T 56 3a) 3
UM-OC-2T 60 3a) 1C
UM-OC-3T 55 3a) 1
UM-OC-4T 78 3a) 3
CHTN-OS-002 83 3 3C
CHTN-OS-018 57 2 3C
CHTN-OS-020 44 3 3C
CHTN-OS-046 53 2 2C
CHTN-OS-081 74 3 3C
UM-OS-07 54 3 3C
UM-OS-10 61 1 3
UM-OS-11 43 3 3C
a) Clear cell carcinomas cannot be graded using the WHO or
FIGO systems (Y. Shimizu et al., Cancer, 1998) and were clas-
sified as grade 3 as recommended by the NCCN Practice
Guidelines for Ovarian Cancer.
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extraction, the vials were filled with fresh lysis buffer again
and homogenized for 2 min. These two lysis solutions were
combined in 10-mL polycarbonate centrifuge tubes and in-
soluble material was precipitated by centrifugation at
35 000 rpm for 1 h (80Ti Beckman Ultracentrifuge). Tissue
lysates were stored at 2807C.
2.2 Chromatofocusing
CF is a weak anion exchange technique for separating
proteins according to their pI. In our work, CF was per-
formed on an HPCF-1D column (25062.1 mm) (Epro-
gen, Darien, IL). A pH gradient was formed using start
buffer (SB) and eluent buffer (EB) on the column. The
pH of the SB, which contains 25 mM bis-Tris (Sigma),
6 M urea (Sigma) and 0.2% OG, was set slightly above the
upper limit of the pH gradient (pH 7.2). The pH of the
EB, which contained 1:10 diluted polybuffer 74, 6 M urea
and 0.2% OG, was adjusted to the value determined for
the lower limit of the pH gradient (4.0). The pH of SB
and the EB were adjusted with iminodiacetic acid. The
2.5-mL lysates were exchanged with 3 mL SB using a PD-
10 column (Amersham Pharmacia, Piscataway, NJ) to
avoid the effect of salt on the weak anion exchange
column.
The column was equilibrated with the SB until the pH
of the effluent was the same as the pH of SB and the A of
UV (280 nm) was stable. The pH of the eluent was mon-
itored online by a post-UV detector pH flow cell (Lazar Re-
search Laboratories, Los Angeles, CA). The buffer ex-
changed tissue lysates (7.1 mg) were loaded onto the CF
column by multiple injections to prevent overloading. No
replicate CF runs were performed due to the limited
amount of tumor available for each sample. Proteins with
pI under pH 7.2 will bind to the column. Once both the pH
of the effluent and the A of UV were stable, the column was
eluted with the EB to start the gradient. Proteins elute out in
order of their pI at flow rate of 0.2 mL/min. The proteins
eluted out were collected from pH 7.2 to pH 4.0 in 0.2 pH-
unit intervals and protein fractions were subsequently
stored at 2807C for later use.
2.3 LC/ESI-TOF-MS
The LC separation was performed at a flow rate of 0.4 mL/
min on an ODS IIIE (33 mm64.6 mm) column packed with
1.5 mm non-porous silica beads derivatized with C18 (Epro-
gen). As solvent A, 0.1% TFA and 0.3% formic acid (FA) in
H2O was used. The percentage of TFA and FA in ACN was
used as solvent B in the gradient. The column was equili-
brated with 5% of solvent B until the A of UV (214 nm)
(Thermo separation products sp UV 200, FL) became stable
and the protein fraction (pH 5.4–5.2) from CF separation
was applied to the column, which was placed in a column
heater to maintain the column temperature at 657C. The
gradient was run from 5 to 25% in 2 min, 25 to 35% in
5 min, 35 to 45% in 10 min, 45 to 75% in 10 min, and 75 to
100% in 2 min and from 100% back to 5% in 1 min. A post-
column splitter was used to split the effluent into half. Half
of the effluent was delivered into the source of ESI-TOF
(LCT, Waters, US). The other half of the effluent was passed
through a Beckman model 166 UV absorption detector
(214 nm) and was collected using a Beckman SC-100 frac-
tion collector for MALDI-TOF MS analysis. The LCT para-
meters were set as follows: desolvation temperature 3007C,
source temperature 1107C, desolvation gas 970 L/h, capillary
voltage 13200 V, sample cone 135 V, extraction cone 12 V,
and rf voltage 750 V. Before sample injection, the external
calibration was utilized with the direct infusion of NaI-CsI
solution by a syringe pump. Bovine insulin (0.2 mg) was
mixed with samples and injected into the LC-MS for calibra-
tion and quantification.
Maxent1 software was used for LCT data analysis. The
total ion chromatogram (TIC) was scanned for regions that
contain redundant multiple-charged peaks, and those
regions were combined for deconvolution (as described in
Supplementary Figs. 2 and 4). The deconvoluted peaks were
subsequently combined into a single mass spectrum, which
was converted to a text file for input into the 2-D mapping
software (Proteovue) written in-house.
2.4 Tryptic digestion of the LCT fractions and peptide
preparation for MALDI-MS analysis
After collection, fractions from the LCT separation were
concentrated down to 20 mL using a Speedvac concentrator
(Labconco, Kansas City, MO). To the reduced volume frac-
tions, 10% v/v 10 mM DTT (Sigma), 10 mL 1 M NH4HCO3
(Sigma) and 0.25 mg of TPCK-treated trypsin (Promega,
Madison, WI) were added. The fractions were then incubated
at 377C for 24 h. After 24-h incubation, 2.5% v/v TFA was
added into each fraction to stop digestion. Prior to MALDI
analysis, the peptide mixtures were desalted and con-
centrated using 2 mm C18 Ziptip (Millipore, Billerica, MA)
with a final elution of 5 mL of 50% ACN with 0.1% TFA.
Sample spotting was performed by layering 0.5 mL of matrix
on top of a 0.5 mL portion of purified peptide solutions. The
MALDI matrix was prepared by diluting saturated CHCA
(Sigma) solution made in 50% v/v ACN and 1% v/v TFA
with the same solution at a 1:4 ratio v/v. For internal calibra-
tion, 50 fmol/mL of Angiotensin I, Adrenocorticotropic hor-
mone (ACTH) 1–17 and ACTH 18–39 (Sigma) were intro-
duced in the matrix as internal standards.
2.5 MALDI-TOF-MS
MALDI-MS was performed on a Micromass TofSpec2E
(Micromass/Waters, Milford, MA) with delayed extraction in
the reflectron mode using a nitrogen laser (337 nm). The
operating voltage was 20 kV with 18-kV extraction voltage.
The pulse voltage was set in the range of 2100–2500 V
depending on the peptide masses under investigation. The
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2006, 6, 5846–5856 Clinical Applications 5849
delay time was 520 ns and the reflectron was at a 1:3 ratio to
the source voltage. The tryptic peptide masses were meas-
ured over a range of 800–4000 Da. Three internal standards
were used to calibrate the instrument with typical 50 ppm
mass accuracy or less. The monoisotopic peptide mass list
was submitted to the Swiss-Prot database using the MS Fit
search engine (http://prospector.ucsf.edu/ucsfhtml4.0/
msfit.htm) for protein identification. The search was per-
formed allowing one missed cleavage and possible mod-
ifications such as oxidation and phosphorylation. The mo-
lecular weight ranged from 5000 to 100 000 and there was no
restriction on the pH range. A strong hit (an identification
with high confidence) meets the following criteria:
(i) MOSWE score is at least on the order of 104 with five
minimum matched peptides; (ii) the protein is ranked first
or second by the database search engine; (iii) the percentage
of coverage is at least 30%; and (iv) the matched peptides
include the most abundant peak in the MALDI spectrum.
2.6 LC-MS/MS
In order to confirm the MALDI-TOF results, tandem MS
experiments were performed using the linear IT MS (LTQ,
Thermo Finnigan, San Jose, CA). The capillary transfer tube
was set at 2007C and ESI voltage at 4.0 kV. A sheath gas flow
of 12 arbitrary units was used. The ion activation was
achieved by utilizing helium at normalized collision energy
of 35%. All MS/MS data obtained were analyzed using the
TurboSequest feature of Bioworks 3.1 SR1 (Thermo Finni-
gan). By allowing up to two missed cleavages, peptide ions
were automatically assigned with the Xcorr values to con-
sider .3.5 for 13 ions, .2.5 for 12 ions, and .1.5 for
11 ions and the DCn of 0.1 or higher. Data and results for
the identification of Annexin IV (ANXA4) are included in
Supplementary Fig. 5 and Table 1.
2.7 Immunohistochemistry
An existing ovarian carcinoma tissue microarray [8] contain-
ing 10 clear cell and 25 serous ovarian carcinomas from the
Surgical Pathology archives of the University of Michigan
Health System was immunohistochemically stained with
anti-ANXA4 antibody (1:200 dilution, Santa-Cruz Biotech).
Antigen-antibody complexes were detected with the avidin-
biotin peroxidase method using 3,3’-diaminobenzidine as a
chromogenic substrate (Vector Laboratories). Immuno-
stained sections were lightly counterstained with hematox-
ylin and then examined by light microscopy.
2.8 Statistical analysis
Protein abundances for each sample were first log (base 2)
transformed and summed with consecutive, non-over-
lapping windows of width 26104 PPM. That is, starting at a
lower mass bound of 5000 Da, the first window spanned
from 5000 to 5000(1 1 26104/106) Da = 5100 Da, the second
window spanned from 5100 Da to 5100(1 1 26104/106) Da
= 5202 Da, and so on. At a typical protein mass of 50 kDa, the
mass window was 1000 Da wide, with wider windows at
greater masses and narrower windows at lesser masses. The
reason for constructing the windows in this way is that
absolute measurement error is greater for larger proteins,
and larger proteins are presumed to have greater mass var-
iation due to PTM.
Next, two-sample t-tests were performed within each
window, to compare the mean expression level in the clear
cell group from the mean expression level in the serous
group. A significant difference was defined when the t-test p-
value was less than 0.01 and when the levels within each
group had standard deviation greater than 1026. For display
purposes (e.g. Fig. 1), bands with significantly greater
expression in clear cell samples were colored pink and bands
with significantly greater expression for serous samples were
colored cyan. Bands in which a nonzero abundance was
detected in every sample were colored yellow.
Principal component analysis (PCA) and complete
5000 PPM-linkage hierarchical clustering were performed
using the covariance matrix of the window-level abundance
data as described above. Pearson correlation coefficients be-
tween the window-level aggregated masses were used in the
hierarchical clustering. All mass windows were used in both
analyses.
3 Results and discussion
3.1 2-D liquid phase mass mapping
A 2-D liquid phase mass mapping method has been devel-
oped in our laboratory and for the first time applied to profile
protein expression in primary tumor tissues (Fig. 2). Pro-
teins extracted from two different histological types of ovar-
ian carcinoma samples (clear cell and serous carcinomas)
were separated by utilizing this 2-D liquid phase separation
method in order to identify proteins differentially expressed
in serous versus clear cell carcinomas. This analytical
approach fractionated proteins by CF in the first dimension
based on pI, and each pH fraction was further separated by
nonporous (NPS)-RP-HPLC in the second dimension. The
protein eluents from NPS-RP-HPLC were interfaced online
to ESI-TOF to obtain an accurate and reproducible protein
intact molecular weight. The 2-D mass maps of each tissue
were finally generated by the 2-D liquid phase separation
method, which also allows for highly accurate protein profile
comparisons between the two different histological types of
ovarian cancer. Figure 1 shows the 2-D comparison mass
map of 16 clear cell and 8 serous ovarian cancer samples
generated from a selected pH fraction (5.4–5.2), where the
clear cell samples are labeled with a -C and the serous with
a -S. The horizontal and vertical dimensions of the 2-D pro-
tein content map are plotted in terms of the selected pI range
and protein intact MW, respectively. Each vertical lane on the
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Figure 1. Comparison of a
selected pI range (pH 5.4–5.2) in
2-D mass map of 16 clear cell
and 8 serous ovarian carcino-
mas. Each lane represents a
sample and the intensity of each
band is proportional to the pro-
tein’s concentration at a given
MW value. Differentially expres-
sed proteins are highlighted in
different colors.
Figure 2. Experimental work flow of 2-D liquid phase mass map-
ping method followed by protein identifications with PMF analy-
sis and LC-MS/MS sequencing.
map represents the protein content of the same selected
pH fraction collected from each sample. Each band repre-
sents each protein eluted from RP-HPLC and detected by
ESI-TOF. For identification of differentially expressed pro-
teins between the clear cell and serous sample groups, the
protein mass range was divided into windows of
20 000 PPM width. That is, a window that starts at K Dal-
tons ends at K 1 K/20 Daltons. This window was chosen
to include possible isoforms due to posttranslational mod-
ifications. Other windows of 10 000 PPM and 5000 PPM
were also tested and, generally, similar results were
obtained. A non-overlapping sequence of windows was
constructed covering the entire measured range. Within
each of these windows, the total measured protein amount
was summed for each sample, and these sums were com-
pared between the 8 serous samples and the 16 clear cell
samples using two-sample t-tests. Figure 1 shows the result
of this analysis for one selected pI range. Pink bands in
the figure correspond to mass ranges that are significantly
more abundant in clear cell samples. Blue bands corre-
spond to mass ranges that are significantly more abundant
in serous samples. Yellow bands correspond to mass
ranges in which all 24 samples have some level of meas-
ured protein expression.
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Taking a more detailed look at differential expression,
Fig. 3 shows the total measured protein per sample for two
selected windows identified as differentially expressed using
the t-test analysis. The expression level of each protein is
calculated based on the total ion count of each protein peak
detected by ESI-TOF. The two adjacent pH fractions were
checked and the peak areas of any proteins that may cross
over two or three fractions were combined. Normalization
was employed by two adjustments based on sample size (the
total amount of protein injected from each tissue sample)
and internal standard response (the quantity of bovine insu-
lin internal standard added). One of the selected windows
shows a protein band that is more abundant in clear cell
samples, and the other shows a protein band that is more
abundant in serous samples. Note that in both cases, the
sample class with lower expression actually has zero expres-
sion for all but one sample, which expresses at an inter-
mediate level compared to the other group.
3.2 Comparison of global expression patterns
distinguishes clear cell from serous ovarian
carcinomas
Previously, Schwartz et al. [8] reported that the clear cell sub-
type of ovarian carcinoma displays a distinct gene expression
pattern among various subtypes of ovarian cancers. The
protein expression patterns in 16 clear cell and 8 serous
ovarian cancer samples were compared using the 2-D mass
Figure 3. Comparisons of select-
ed differentially expressed pro-
teins (Annexin A4 (a) and Ras-
related protein Rab-3D (b)) be-
tween clear cell and serous ovar-
ian carcinoma samples.
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mapping method to search for signatures that might differ-
entiate the two groups. An alternative way of looking at the
data is to focus on the interrelationships among the samples
in terms of their overall patterns of protein expression, with-
out aiming to identify specific bands of interest. To do this,
again the protein amounts are summed within 20 000-PPM
bands, and then log-transformed to reduce the skew in the
data. In-house developed software based on PCA is then used
to reduce the data to a set of points in the plane that can be
displayed as a scatter plot (Fig. 4). Each point in this plot
corresponds to one of the samples, and the points are dis-
tributed such that similar sample pairs fall closer together in
the plot compared to less similar sample pairs (where simi-
larity is based on all protein expression levels in all measured
fractions). The points are colored to indicate the tissue type.
The fact that the points corresponding to serous (green) and
clear cell (red) samples are well separated indicates that the
major source of variation in the data can be attributed to
whether a sample is of clear cell or serous origin. Note that
the PCA procedure does not have access to the tissue type
information. Therefore, this finding is not due to over-fitting
of the data. Obviously, differences in protein expression pat-
tern between clear cell and serous ovarian tumor samples are
able to discriminate two different histological types of ovar-
ian cancer. As expected, this result is consistent with our
previously published mRNA expression study, which indi-
cated that the clear cell subtype of ovarian carcinomas dis-
plays a distinct gene expression signature in comparison
with other types of ovarian cancers [8].
3.3 Hierarchical clustering analysis
An alternative method that has similar goals as PCA is hier-
archical clustering, as shown in Fig. 5. This method aims to
define a sequence of clusters of the samples, starting with a
partition in which each sample is in its own cluster, and
ending with a partition in which every sample is in the same
Figure 4. Principal component analysis (PCA) scatter plot with
samples annotated with histological type. The plot clearly shows
that clear cell and serous samples segregate out based upon the
2-D mapping information.
cluster. Greatest interest focuses on the large clusters
obtained by making a vertical cut toward the right side of
Fig. 5. It can be seen that the final step of the clustering al-
gorithm (the rightmost join in the figure) is between a ho-
mogeneous group of serous samples and a homogeneous
group of clear cell samples. This indicates, consistently with
PCA, that the most important source of variation in the
ovarian cancer data is histological type, and hierarchical
clustering based on the protein expression of the 16 clear cell
and 8 serous ovarian tissue samples results in complete
separation of the two ovarian cancer subtypes. This result is
similarly in concert with previously published statistical
results based on a gene expression comparison among dif-
ferent histological types of ovarian cancers [17].
3.4 Protein identification
The 2-D liquid phase protein separation is readily interfaced
to protein identification by mass spectrometry. Protein solu-
tion eluting from RP-HPLC is split into two streams. One is
directly interfaced to ESI-TOF MS to obtain an intact protein
MW value. The remainder is collected online by a fraction
collector and further identified by PMF using MALDI-TOF
MS and protein IDs of interest (fold change difference
higher than 3) are also confirmed by LC/MS/MS. Proteins
identified as potential histological-type-specific biomarkers
and associated proteins from pI fractions pH 5.4–5.2 and
5.2–5.0 are summarized in Tables 2 and 3, respectively.
These proteins may serve as type-specific diagnostic markers
and some may ultimately allow treatment to be better tai-
lored to each subtype of ovarian cancer. Of particular interest
is ANXA4, which belongs to a large family of glycoproteins
that bind both Ca21 ions and negatively charged phospholi-
pids. The annexins are involved in several important biolog-
ical functions, such as exocytosis, anticoagulation, and anti-
inflammation [18]. Furthermore, ANXA4 is a substrate for
protein kinase C, which may act as regulator of membrane
fusion and possesses the structural properties necessary to
form ion channels [19–22]. These properties suggest that it
may be involved in processes such as growth, differentiation
and transformation [23]. It has also been shown that ANXA4
plays an important role in the morphological diversification
and dissemination of clear cell renal carcinomas [24]. We
found that ANXA4 was highly expressed in all of 16 clear cell
carcinoma samples, but in very few serous tumor samples.
In order to validate our proteome profiling data, we used
immunohistochemical staining to evaluate expression of
ANXA4 in an independent set of ovarian carcinomas repre-
sented in an ovarian cancer tissue microarray (details of the
TMA provided in reference [8]). As expected, immunohisto-
chemical staining confirmed markedly increased expression
of ANXA4 in clear cell compared to serous carcinomas
(Fig. 6).
These findings suggest that clear cell and serous sub-
types of ovarian cancers have different pathogenesis path-
ways and that ANXA4 should be examined further to deter-
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Figure 5. Hierarchical clustering dendrogram of
clear cell and serous ovarian carcinomas.















Annexin A4 (Annexin IV) P09525 35 883 35 995 1300 (655) 1.51E109 58
ATP synthase beta chain (mitochondrial
precursor)
P06576 56 560 55 199 2289 (681) 9.85E108 42
Alpha enolase P06733 47 169 47 123 2154 (647) 5.22E109 58
L-Lactate Dehydrogenase M chain P00338 36 689 36 600 295 (632) 2.83E105 40
Extracellular superoxide dismutase [Cu-Zn]
precursor
P08294 25 881 26 120 2199 (653) 4.12E106 35
Ras-related protein Rab-3D O95716 24 758 24 900 2233 (674) 7.09E106 32
Zinc finger protein 125 (HZF-3) P35274 13 676 13 763 265 (629) 7.88E104 38

















Keratin, type II cytoskeletal 8 P05787 53 675 53 617 114 (65) 2.11E110 61
Keratin, type II cytoskeletal 7 P08729 51 418 51 841 161 (628) 4.54E108 55
Keratin, type I cytoskeletal 18 P05783 48 058 47 969 19 (64) 8.14106 43
Wilm’s tumor 1-associating protein Q15007 44 244 41 661 1155 (621) 6.15E108 42
Activator 1 36 kDa subunit (Replication factor C
36 kDa subunit)
P40937 38 497 36 336 122 (610) 7.06E106 30
Proto-oncogene C-crk (P38) P46108 33 872 32 569 165 (627) 3.27E104 29
Spindlin (Ovarian cancer-related protein) Q9Y657 27 077 25 813 174 (611) 5.33E104 35
ATP synthase D chain, mitochondrial (My032
protein)
O75947 18 491 18 403 13 (62) 2.16E107 46
Group X secretory phospholipase A2 precursor O15496 17 132 17 214 12.5 (61) 2.42E103 27
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Figure 6. Immunohistochemical analysis of ANXA4 expression
in primary ovarian carcinomas. Staining of representative clear
cell and serous carcinomas is shown.
mine its utility as a marker of clear cell carcinomas. Clear cell
adenocarcinoma of the ovary is also known as a strongly
chemoresistant tumor in contrast to most of the ovarian sur-
face epithelial carcinomas [25–28]. Notably, ANXA4 has been
implicated in drug resistance after exposure of cells to pacli-
taxel [29].
We also identified several proteins highly expressed in
the serous subtype compared with clear cell ovarian tumor
samples (Table 2). WT-1 (Wilm’s tumor 1), for example, has
been described as a highly sensitive marker of serous ovarian
carcinoma [30]. This protein was not expressed in the clear
cell subtype, while it was highly expressed in the serous
cases. WT-1 is a DNA-binding protein, located in the nucleus,
which plays a critical role in the development of the geni-
tourinary tract. Recent microarray gene expression studies
confirmed our findings [17], and, using immunohistochem-
istry, we have previously confirmed [8] high expression of
WT-1 protein in serous ovarian carcinomas compared to
clear cell carcinomas.
Cytokeratin 7, cytokeratin 8 and cytokeratin 18 have both
structural and signaling functions and have been identified
as being differentially expressed in the serous cancers.
Expression of cytokeratins in human tumors has been
extensively studied and some researchers have demonstrated
that different cell types in human breast tissues express a
different array of cytokeratins [31–35]. The Ras-related pro-
tein Rab-3D, which plays a critical role in regulating the
eukaryotic cell cycle as a shuttling factor through the nuclear
pore complex [36] or membrane transport mechanisms [37],
was detected in high abundance only in serous samples.
Proto-oncogene C-crk (P38), which is involved in phagocy-
tosis of apoptotic cells and cell motility, was also found to be
highly expressed in serous ovarian tumor samples. Various
data indicate a role for Crk in growth factor-stimulation [38,
39]. Spindlin is another differentially expressed protein
found in the serous carcinomas, with a potential role in cell-
cycle regulation during the transition from gamete to
embryo. It has been submitted to the EMBL/GenBank/DDBJ
databases as an ovarian cancer-related protein by W. Yue and
colleagues [40]. Notably, cytokeratin 7, cytokeratin 8, cytoker-
atin 18, Ras-related protein Rab-3D and proto-oncogene C-
crk (P38) were relatively poorly expressed (not detected by
ESI) in the clear cell cancers compared to serous tumors.
These three types of keratin were consistently detected in
8 serous samples but not in most of clear cell samples, where
all 24 tissue samples were processed at one time. They were
previously proposed as biomarkers of ovarian cancer [13, 41,
42] and it is unlikely that they are due to contamination. Our
findings suggest that these markers are subtype-specific and
clear cell ovarian cancers should be considered separately in
studies of these unregulated proteins as a diagnostic test for
ovarian carcinomas.
Finally, we note that some of the proteins found to be
differentially expressed between clear cell and serous ovar-
ian carcinomas would not have been identified through
mRNA-based gene expression profiling. We used our exist-
ing ovarian cancer oligonucleotide microarray data to
examine mRNA expression corresponding to several of the
differentially expressed proteins listed in Tables 2 and 3.
Some genes, such as ANXA4, WT-1 and HZF-3, show con-
cordant differential expression of the corresponding
mRNA. For HZF-3, high expression in serous carcinomas
appears to be driven by only a subset of the tumors, while
expression of ANXA4 and WT-1 is more uniformly
increased in clear cell and serous carcinomas, respectively.
Notably, some genes such as SPN, C-CRK (p38), and Rab-
3D do not show differential expression of the correspond-
ing mRNA (Fig. 7). Although not unexpected, this finding
underscores the notion that gene expression profiling may
fail to identify a substantial number of genes whose protein
products play biologically significant roles in disease
pathogenesis or could serve as clinically useful biomarkers.
In their comparison of the proteome and transcriptome in
human platelets, McRedmond and colleagues [43] noted
that messages for approximately 30% of proteins could not
be detected, possibly representing RNA destruction follow-
ing protein synthesis. A number of other post-transcrip-
tional and post-translational modifications (PTM) of mRNA
and proteins, respectively, could contribute to discordance
between the mRNA and protein data for specific genes. In
contrast to the static nature of the genome, which is essen-
tially identical in every cell of an organism, the proteome is
dynamic, constantly changing and responding to internal
and external stimuli [44]. Proteomic technologies also allow
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Figure 7. Relative RNA expres-
sion levels of ANXA4, HZF-3,
WT1, RAB3D, SPIN and CCRK
genes in primary ovarian clear
cell and serous carcinoma sam-
ples using oligonucleotide
microarray analysis. ANXA4 and
HZF3 are represented by two
probe sets in the microarray.
more accurate identification of the protein changes
caused by the disease [45, 46]. At the protein level, distinct
changes occur during the transformation of a healthy cell
into a malignant cell, including PTM and protein activi-
ties, interactions and localization, all of which may affect
cellular function. Identifying and understanding these
changes is the underlying theme in cancer proteomics
[47–49].
4 Concluding remarks
A 2-D liquid phase mass mapping method has been applied
to explore variations in protein expression related to histo-
logical subtypes of ovarian cancer. The 2-D pI/mass maps of
clear cell and serous ovarian tumor tissue samples were
generated and used for interlysate comparison of protein
expression between the different samples. Two histological
types of ovarian tumor tissues were successfully dis-
tinguished based on protein expression patterns. In this
study, differentially expressed proteins between the two sub-
types were identified by PMF as promising candidates of
type-specific biomarkers, which can also be utilized as a
comprehensive protein expression signature for each sub-
type. Recognition of such a protein expression signature may
ultimately allow therapeutic approaches to be better tailored
to the characteristics of each tumor type. Identification of
these type-specific markers should eventually facilitate
future studies aimed at improving the diagnosis and treat-
ment of ovarian cancers.
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